Annovis Bio (NYSE: ANVS) has announced it will deliver three presentations at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, scheduled for Nov. 16-19, 2026, in Boston. The presentations will focus on the company’s investigational oral therapy buntanetap, covering its mechanism of action, the design and baseline characteristics of its pivotal Phase 3 study in early Alzheimer’s disease, and the use of artificial intelligence to predict blood-brain barrier permeability of late-stage Alzheimer’s drug candidates. The move underscores the company’s efforts to maintain visibility with clinicians and researchers as it approaches a critical data readout.
The inclusion of an AI-focused presentation signals Annovis’s interest in leveraging computational tools to address one of the central challenges in central nervous system drug development: achieving effective blood-brain barrier penetration. The company’s lead candidate, buntanetap, is an investigational once-daily oral therapy designed to inhibit the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By targeting multiple proteins implicated in neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
The Phase 3 trial design and baseline characteristics presentation will offer stakeholders a detailed look at the study’s structure and patient population, which is particularly relevant as the company prepares for a pivotal clinical data readout in early 2027 and eventual New Drug Application submission. The conference program includes an oral presentation on Nov. 19 by Alexander Morin, director of strategic communications, and two poster presentations on Nov. 16-17, one of which will be delivered by Chief Scientific Officer Cheng Fang.
For investors, the CTAD presentations represent a key opportunity to gauge the rigor of Annovis’s clinical program and the scientific rationale behind buntanetap. The company’s shares trade on the New York Stock Exchange under the ticker ANVS, and the latest updates are available in its newsroom at https://nnw.fm/ANVS. Annovis is headquartered in Malvern, Pennsylvania, and is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. More information about the company can be found at www.annovisbio.com, and the company can be followed on LinkedIn, YouTube, and X. The full press release is available at https://nnw.fm/2k4SQ.
The CTAD conference is a significant venue for Alzheimer’s research, and Annovis’s participation highlights its commitment to transparency and scientific engagement. The AI component, in particular, could offer insights into how the company is using advanced analytics to optimize drug development. As the company moves closer to its Phase 3 data readout, these presentations may help shape expectations and demonstrate the depth of its pipeline. For more details on Annovis Bio, visit the Annovis Bio (NYSE: ANVS) profile page.
